Aday JS

Department of Psychiatry and Behavioral Sciences, Translational Psychedelic Research (TrPR) Program, Weill Institute for Neurosciences, University of California, San Francisco, USA.

30 papers · 2 preprints · ORCID

ArticlePsilocybin

A randomized crossover trial comparing the acute physiological and psychological effects of botanical formulations of oral psilocybin, oral psilocin, and sublingual psilocin.

Tai ML, Szigeti B, Downey AE +12

Europe PMC2026
ArticlePsilocybin

Microdosing psychedelics: What, why, when, and how often? Insights from an international survey of people who use psychedelics.

Petranker R, Syed OA, Sobolenko V +5

Europe PMC2026
ArticlePsilocybin

Classic Psychedelics for Chronic Pain: A Critical Review of the Literature and Practical Advice for Clinicians.

Boehnke KF, Pouyan N, Aday JS

Europe PMC2026
ArticlePsychedelics

Major life changes following psychedelic use: A retrospective survey among people using psychedelics naturalistically.

Aday JS, Glynos NG, Baker AK +7

Europe PMC2026
ArticleAyahuasca

Preliminary effects of ayahuasca on mental and physical health: A systematic review of prospective studies.

Haupt MJ, Carra S, Boehnke KF +1

Europe PMC2026
ArticlePsychedelics

Blunted Psychedelic Drug Effects in Older Adults.

Aday JS, Carhart-Harris RL, Boehnke KF

Europe PMC2026
ArticlePsychedelics

Development of a mandarin version of the five dimensional altered states of consciousness (5D-ASC) rating scale.

Aday JS, Zong Z, Song J +2

Europe PMC2026
ArticlePsilocybin

Disengaged: A systematic review of community engagement in psychedelic-assisted therapy research.

Reid MR, Song J, Boehnke KF +2

Europe PMC2026
ArticleMDMA

A meta-analytic analysis of the acute effects of MDMA on empathy and emotion recognition in humans.

Peled-Avron L, Aday JS, Pantoni MM +2

Europe PMC2025
ArticlePsilocybin

Best practices for first psychedelic experiences: harm reduction advice from the psychedelic community.

Kruger DJ, Mersereau G, Sullivan A +5

Europe PMC2025
ArticlePsychedelics

The Relationship Between Psychedelic Use and Positive Adult Development in Emerging Adulthood: An Integrative Review.

Payne J, Robinson O, Arnaud KS +4

Europe PMC2025
PreprintPsilocybin

Blunted psychedelic drug effects in older adults

Aday JS, Carhart-Harris R, Boehnke KF

Europe PMC2025
PreprintPsilocybin

Blunted psychedelic drug effects in older adults

Aday JS, Carhart-Harris R, Boehnke KF

Europe PMC2025
ArticlePsychedelics

Pictorial representation of illness and self measure (PRISM): A putative transdiagnostic tool for evaluating therapeutic effects of psychedelic treatments.

Pouyan N, Aday JS, Harte SE +11

Europe PMC2025
ArticlePsychedelics

Addressing blinding in classic psychedelic studies with innovative active placebos.

Aday JS, Simonsson O, Schindler EAD +1

Europe PMC2025
ArticlePsychedelics

Perceived Impact of Psychedelics on Sexual, Gender, and Intimate Relationship Dynamics: A Mixed-Methods Investigation.

Kruger DJ, Argyri EK, Mogilski JK +4

Europe PMC2026
ArticlePsilocybin

Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial.

Aday JS, McAfee J, Conroy DA +16

Europe PMC2025
ArticlePsychedelics

Psychedelic Therapist Sexual Misconduct and Other Adverse Experiences Among a Sample of Naturalistic Psychedelic Users.

Kruger DJ, Aday JS, Fields CW +5

Europe PMC2025
ArticlePsilocybin

Psychedelics and chronic pain: self-reported outcomes on changed substance use patterns and health following naturalistic psychedelic use.

Glynos NG, Baker A, Aday JS +4

Europe PMC2025
ArticlePsilocybin

Going Underground: Demographics, Services, and Best Practices Endorsed by Practitioners Providing Support for Naturalistic Psychedelic Use.

Glynos NG, Baker A, Aday JS +5

Europe PMC2025
ArticleDMT

Editorial: Down the rabbit hole - the psychological and neural mechanisms of psychedelic compounds and their use in treating mental health and medical conditions.

Peled-Avron L, Aday JS, Kalafateli AL +2

Europe PMC2024
ArticlePsilocybin

Psychedelic-assisted psychotherapy: where is the psychotherapy research?

Aday JS, Horton D, Fernandes-Osterhold G +4

Europe PMC2024
ArticlePsychedelics

Psychedelic Research as a Career Path: A Roundtable Discussion with Early Career Researchers in the Field.

Aday JS, Mason NL, Wood BJ +5

Europe PMC2024
ArticlePsilocybin

Psychedelic substitution: altered substance use patterns following psychedelic use in a global survey.

Glynos NG, Aday JS, Kruger D +3

Europe PMC2024
ArticleAyahuasca

Effects of Ayahuasca on Gratitude and Relationships with Nature: A Prospective, Naturalistic Study.

Aday JS, Bloesch EK, Davis AK +4

Europe PMC2025
ArticleMDMA

Expectancy Effects Cannot Be Neglected in MDMA-Assisted Therapy Research.

Flameling LJ, Aday JS, van Elk M

Europe PMC2023
ArticleKetamine

Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry.

Aday JS, Barnett BS, Grossman D +3

Europe PMC2023
ArticlePsilocybin

Personal Psychedelic Use Is Common Among a Sample of Psychedelic Therapists: Implications for Research and Practice.

Aday JS, Skiles Z, Eaton N +6

Europe PMC2023
ArticlePsychedelics

Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials.

Aday JS, Heifets BD, Pratscher SD +3

Europe PMC2022
ArticlePsychedelics

Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects.

Aday JS, Davis AK, Mitzkovitz CM +2

Europe PMC2021
ArticlePsychedelics

Psychedelics and virtual reality: parallels and applications.

Aday JS, Davoli CC, Bloesch EK

Europe PMC2020
ArticleLSD

Beyond LSD: A Broader Psychedelic Zeitgeist during the Early to Mid-20<sup>th</sup> Century.

Aday JS, Bloesch EK, Davoli CC

Europe PMC2019